Revenue breakdown: Franchise Fees (67.8%), Products Sales Nonfranchisees (16.2%), Product Sales Franchisees (16%).
6-K
On March 6, 2026, Park Ha Biological Technology Co., Ltd. received a letter from Nasdaq's Listing Qualifications Department stating that its Class A ordinary shares achieved a closing bid price at or above $1.00 per share for 10 consecutive business days from February 20 through March 5, 2026, regaining compliance with Nasdaq Listing Rule 5550(a)(2). The matter is now closed.